Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees

详细信息    查看全文

• 作者：Richard H Chapman (1)
  Jason Yeaw (1)
  Craig S Roberts (2)
  
• 刊名：BMC Cardiovascular Disorders
• 出版年：2010
• 出版时间：December 2010
• 年：2010
• 卷：10
• 期：1
• 全文大小：616KB
• 参考文献：1. World Health Organization: Cardiovascular diseases (CVDs). Fact sheet number 317. Updated September 2009. [index.html" class="a-plus-plus">http://www.who.int/mediacentre/factsheets/fs317/en/index.html]
  2. Neaton JD, Wentworth D: Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. / Arch Intern Med 1992, 152:56鈥?4. CrossRef
  3. Thomas F, Bean K, Guize L, Quentzel S, Argyriadis P, Benetos A: Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. / Eur Heart J 2002, 23:528鈥?35. CrossRef
  4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). / JAMA 2002, 288:2981鈥?997. CrossRef
  5. Sever P, Dahl枚f B, Poulter N, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen S, Kristinsson A, McInnes G: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. / Lancet 2003, 361:1149鈥?158. CrossRef
  6. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman M, Weiss N: Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. / JAMA 2003, 289:2534鈥?544. CrossRef
  7. LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. / JAMA 1999, 282:2340鈥?346. CrossRef
  8. Amarenco P, Labreuche J, Lavall茅e P, Touboul PJ: Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. / Stroke 2004, 35:2902鈥?909. CrossRef
  9. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. / Lancet 2005, 366:1267鈥?278. (Erratum in: / Lancet 2005;366(9494):1358; / Lancet 2008;371(9630):2084) CrossRef
  10. Patel BV, Leslie RS, Thiebaud P, Nichol MB, Tang ST, Solomon H, Honda D, Foody JM: Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. / Vasc Health Risk Manag 2008, 4:673鈥?81.
  11. Chapman RH, Pelletier EM, Smith PJ, Roberts CS: Can adherence to antihypertensive therapy be used to promote adherence to statin therapy? / Patient Preference Adherence 2009, 3:265鈥?75. CrossRef
  12. Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, Schwartz JS: Predictors of adherence with antihypertensive and lipid-lowering therapy. / Arch Intern Med 2005, 165:1147鈥?152. CrossRef
  13. Chapman RH, Petrilla AA, Benner JS, Schwartz JS, Tang SS: Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study. / Drugs Aging 2008, 25:885鈥?92. CrossRef
  14. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, Poulter N, Primatesta P, Stegmayr B, Thamm M: Hypertension treatment and control in five European countries, Canada, and the United States. / Hypertension 2004, 43:10鈥?7. CrossRef
  15. Dezii CM: A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. / Manag Care 2000,9(9 Suppl):2鈥?.
  16. Julius S, Cohn JN, Neutel J, Weber M, Turlapaty P, Shen Y, Dong V, Batchelor A, Lagast H: Antihypertensive utility of perindopril in a large, general practice-based clinical trial. / J Clin Hypertens 2004, 6:10鈥?7. CrossRef
  17. Benner JS, Pollack MF, Smith TW, Bullano MF, Willey VJ, Williams SA: Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. / Am J Health Syst Pharm 2005, 62:1468鈥?475. CrossRef
  18. Goldman DP, Joyce GF, Zheng Y: Prescription drug cost sharing: associations with medication and medical utilization and spending and health. / JAMA 2007, 298:61鈥?9. CrossRef
  19. Taira N: Nifedipine: a novel vasodilator. / Drugs 2006, 66:1鈥?. Erratum in: / Drugs 2007;67(13):1849 CrossRef
  20. Liberopoulos EN, Florentin M, Mikhailidis DP, Elisaf MS: Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. / Expert Opin Drug Saf 2008, 7:717鈥?25. CrossRef
  21. Bouchard MH, Dragomir A, Blais L, B茅rard A, Pilon D, Perreault S: Impact of adherence to statins on coronary artery disease in primary prevention. / J Clin Pharmacol 2007, 63:698鈥?08.
  22. Perreault S, Dragomir A, Roy L, White M, Blais L, Lalonde L, B茅rard A: Adherence level of antihypertensive agents in coronary artery disease. / Br J Clin Pharmacol 2010, 69:74鈥?4. CrossRef
  23. Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, Borghi C, Brignoli O, Caputi AP, Cricelli C, Mantovani LG: Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. / Circulation 2009, 120:1598鈥?05. CrossRef
  24. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M: A checklist for medication compliance and persistence studies using retrospective databases. / Value Health 2007, 10:3鈥?2. CrossRef
  25. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK: Medication compliance and persistence: terminology and definitions. / Value Health 2008, 11:44鈥?7.
  26. Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, Magid DJ: Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. / Arch Intern Med 2006, 166:1836鈥?841. CrossRef
  27. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS: Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. / Am Heart J 2008, 155:772鈥?79. CrossRef
  28. Benner JS, Chapman RH, Petrilla AA, Tang SS, Rosenberg N, Schwartz JS: Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. / Am J Health Syst Pharm 2009, 66:1471鈥?477. CrossRef
  29. Donnelly LA, Doney AS, Morris AD, Palmer CN, Donnan PT: Long-term adherence to statin treatment in diabetes. / Diabet Med 2008, 25:850鈥?55. CrossRef
  30. LaFleur J, Thompson CJ, Joish VN, Charland SL, Oderda GM, Brixner DI: Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. / Ann Pharmacother 2006, 40:1274鈥?279. CrossRef
  31. Jackson KC, Sheng X, Nelson RE, Keskinaslan A, Brixner DI: Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database. / Clin Ther 2008, 30:1558鈥?563. CrossRef
  32. Gerbino PP, Shoheiber O: Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. / Am J Health Syst Pharm 2007, 64:1279鈥?283. CrossRef
  33. Munger MA, Van Tassell BW, LaFleur J: Medication nonadherence: an unrecognized cardiovascular risk factor. / MedGenMed 2007, 9:58.
  34. Sever PS, Poulter NR, Mastorantonakis S, Chang C, Dahlof B, Wedel H: Coronary heart disease benefits from blood pressure and lipid-lowering. / Int J Cardiol 2009, 135:218鈥?22. CrossRef
  35. Sever PS, Poulter NR, Dahlof B, Wedel H, ASCOT Investigators: Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. / J Hypertens 2009, 27:947鈥?4. CrossRef
  36. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2261/10/29/prepub
  
• 作者单位：Richard H Chapman (1)
  Jason Yeaw (1)
  Craig S Roberts (2)
  
  1. US Health Economics & Outcomes Research, IMS Health, Falls Church, VA, USA
  2. Global Outcomes Research, Pfizer Inc, New York, NY, USA
  

文摘

Background Prior studies have found that patients taking single-pill amlodipine/atorvastatin (SPAA) have greater likelihood of adherence at 6 months than those taking 2-pill calcium-channel blocker and statin combinations (CCB/statin). This study examines whether this adherence benefit results in fewer cardiovascular (CV) events. Methods A retrospective cohort study was conducted using administrative claims data from the IMS LifeLink: US Health Plan Claims database, identifying adults already taking CCB or statin (but not both) who had an index event of either initiating treatment with SPAA or adding CCB to statin (or vice versa) between April 1, 2004 to August 31, 2005. Inclusion criteria included age 18+ years, continuously enrolled for minimum of 6 months prior and 18 months following treatment initiation, >1 diagnosis of hypertension, and no prescription claims for SPAA or added CCB or statin for 6 months prior. Exclusion criteria included >1 claim with missing or invalid days supplied, age 65+ years and not enrolled in Medicare Advantage, or history of prior CV events, cancer diagnosis, or chronic renal failure. The primary outcome measure was the rate of CV events (myocardial infarction, heart failure, angina, other ischemic heart disease, stroke, peripheral vascular disease, or revascularization procedure) from 6 to 18 months following index date, analyzed at three levels: 1) all adherent vs. non-adherent patients, 2) SPAA vs. dual-pill patients (regardless of adherence level), and 3) adherent SPAA, adherent dual-pill, and non-adherent SPAA patients vs. non-adherent dual-pill patients. Results Of 1,537 SPAA patients, 56.5% were adherent at 6 months, compared with 21.4% of the 17,910 CCB/statin patients (p < 0.001). Logistic regression found SPAA patients more likely to be adherent (OR = 4.7, p < 0.001) than CCB/statin patients. In Cox proportional hazards models, being adherent to either regimen was associated with significantly lower risk of CV event (HR = 0.77, p = 0.003). A similar effect was seen for SPAA vs. CCB/statin patients (HR = 0.68, p = 0.02). In a combined model, the risk of CV events was significantly lower for adherent CCB/statin patients (HR = 0.79, p = 0.01) and adherent SPAA patients (HR = 0.61, p = 0.03) compared to non-adherent CCB/statin patients. Conclusions Patients receiving SPAA rather than a 2-pill CCB/statin regimen are more likely to be adherent. In turn, adherence to CCB and statin medications is associated with lower risk of CV events in primary prevention patients.